The advent of compact, patient-operated diagnostic devices and AI-based analytics of test data allows physicians to partner with remote monitoring centers and jointly manage patients with retinal disease.
10-year ALOFT study results showed remarkable long-term visual outcomes for patients participating in the Medicare covered, AI-enabled ForeseeHome AMD Monitoring Program, provided by the Notal Vision Monitoring Center. The long-term treatment outcomes of patients whose conversion was detected early using ForeseeHome had an average VA of 20/32 after an average of 2.7 years of treatment.